Home > Research > Publications & Outputs > Breast cancer diagnosis from histopathology ima...

Links

Text available via DOI:

View graph of relations

Breast cancer diagnosis from histopathology images using deep neural network and XGBoost

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published
Close
Article number105152
<mark>Journal publication date</mark>1/09/2023
<mark>Journal</mark>Biomedical Signal Processing and Control
Issue numberPart A
Volume86
Publication StatusPublished
<mark>Original language</mark>English

Abstract

Background and Objective: Globally, breast cancer is one of the most common diseases among women. As a result of the disadvantages of manual analysis, computer-aided diagnosis (CAD) systems are being used to detect images because of their time-consuming and trustworthy capability. With deep learning techniques based on image analysis and classification, CAD systems can efficiently classify images. Methods: This paper proposes methodologies for enhancing the speed and precision of histopathological image classification, which is a challenge for therapeutic measures. We assess three different classifiers and six pre-trained networks. A pre-trained model is used to extract features from images and then feed those extracted features into the extreme gradient boosting (XGBoost) method, which is selected as the final classifier. Our methodology is based on transfer learning and uses histopathological images as input. To evaluate the performance of the proposed method, we use the BreakHis dataset, which presents histopathology images in four magnification levels, i.e., 40X, 100X, 200X, and 400X. Results and Conclusion: The accuracies achieved by the proposed method in 40X, 100X, 200X, and 400X magnifications are 93.6%, 91.3%, 93.8%, and 89.1%, respectively. After analyzing the accuracy achieved in this study, the final method proposed combines the DenseNet201 model as a feature extractor with XGBoost as a classifier.

Bibliographic note

Publisher Copyright: © 2023 Elsevier Ltd